Infigratinib
Bridgebio Pharmaceutical
[]
the biology of upper tract cancer is has signifiant potential for immunotherapy but the prevalence of fgfr3 may be lower than expected. #asco23 
PGY-2 | East Carolina University | Internal Medicine | Hematology and Oncology